High-dose versus standard-dose amoxicillin/clavulanate for clinically-diagnosed acute bacterial sinusitis: A randomized clinical trial

Andrea Matho, Mary Mulqueen, Miyuki Tanino, Aaron Quidort, Jesse Cheung, Jennifer Pollard, Julieta Rodriguez, Supraja Swamy, Brittany Tayler, Gina Garrison, Ashar Ata, Paul Sorum, Andrea Matho, Mary Mulqueen, Miyuki Tanino, Aaron Quidort, Jesse Cheung, Jennifer Pollard, Julieta Rodriguez, Supraja Swamy, Brittany Tayler, Gina Garrison, Ashar Ata, Paul Sorum

Abstract

Background: The recommended treatment for acute bacterial sinusitis in adults, amoxicillin with clavulanate, provides only modest benefit.

Objective: To see if a higher dose of amoxicillin will lead to more rapid improvement.

Design, setting, and participants: Double-blind randomized trial in which, from November 2014 through February 2017, we enrolled 315 adult outpatients diagnosed with acute sinusitis in accordance with Infectious Disease Society of America guidelines.

Interventions: Standard-dose (SD) immediate-release (IR) amoxicillin/clavulanate 875 /125 mg (n = 159) vs. high-dose (HD) (n = 156). The original HD formulation, 2000 mg of extended-release (ER) amoxicillin with 125 mg of IR clavulanate twice a day, became unavailable half way through the study. The IRB then approved a revised protocol after patient 180 to provide 1750 mg of IR amoxicillin twice a day in the HD formulation and to compare Time Period 1 (ER) with Time Period 2 (IR).

Main measure: The primary outcome was the percentage in each group reporting a major improvement-defined as a global assessment of sinusitis symptoms as "a lot better" or "no symptoms"-after 3 days of treatment.

Key results: Major improvement after 3 days was reported during Period 1 by 38.8% of ER HD versus 37.9% of SD patients (P = 0.91) and during Period 2 by 52.4% of IR HD versus 34.4% of SD patients, an effect size of 18% (95% CI 0.75 to 35%, P = 0.04). No significant differences in efficacy were seen at Day 10. The major side effect, severe diarrhea at Day 3, was reported during Period 1 by 7.4% of HD and 5.7% of SD patients (P = 0.66) and during Period 2 by 15.8% of HD and 4.8% of SD patients (P = 0.048).

Conclusions: Adults with clinically diagnosed acute bacterial sinusitis were more likely to improve rapidly when treated with IR HD than with SD but not when treated with ER HD. They were also more likely to suffer severe diarrhea. Further study is needed to confirm these findings.

Trial registration: ClinicalTrials.gov Identifier: NCT02340000.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. CONSORT flowchart of study participants.
Fig 1. CONSORT flowchart of study participants.
Reasons for exclusion before randomization were mostly inferred from chart review. We had 30 dropouts during the course of the study. Reason for dropping out included failure to improve or worsening illness (12), adverse reaction (10), allergic reaction (2), fear of side effects (2), misplaced medication bottle (1), switched to different antibiotic for another infection (1), tablet size too large (1), self-discontinuation because of marked symptom improvement (1), and unknown (1). Some participants had multiple reasons for exclusion or for dropping out.

References

    1. Lemiengre MB, van Driel ML, Merenstein D, Young J, De Sutter AIM. Antibiotics for clinically diagnosed acute rhinosinusitis in adults. Cochrane Database Syst Rev. 2012;10:CD006089 doi:
    1. Chow AW, Benninger MS, Brook I, Brozek Jl, Goldstein EJC, Hicks LA, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72–e112. doi:
    1. File TM Jr., Lode H, Kurz H, Kozak R, Xie H, Berkowitz E, 600 Study Group. Double-blind, randomized study of the efficacy and safety or oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother. 2004;48(9):3323–3331. doi:
    1. Carenfelt C, Lundberg C. Aspects of the treatment of maxillary sinusitis. Scand J Infect Dis. Suppl 1976;82:78–81.
    1. Gehanno P, Darantière S, Dubreuil C, Chobaut JC, Bobin S, Pages JC, et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother. 2002;49:821–826.
    1. Seikel K, Shelton S, McCracken GH Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J. 1997;16(7):710–711.
    1. Canafax DM, Yuan Z, Deka K, Russlie HQ, Giebink GS. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media. Pediatr Infect Dis J. 1998;17(2):149–156.
    1. Piglansky L, Leibovitz E, Raiz S, Greenberg D, Press J, Leiberman A, et al. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy in acute otitis media in children. Pediatr Infect Dis J. 2003;22(5):405–412. doi:
    1. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics. 2004;113(5):1451–1465.
    1. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131:e964–e999. doi:
    1. Brook I, Foote PA, Hausfeld JN. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid. Int J Antimicrob Agents. 2005;26(5):416–419. doi:
    1. Kment G, Georgopoulos A, Ridl W, Mühlbacher J. Amoxicillin concentrations in nasal secretions of patients with acute uncomplicated sinusitis and in paranasal sinus mucosa of patients with chronic sinusitis. Eur Arch Otorhinolaryngol. 1995;252(4):236–238.
    1. Dinis PB, Monteiro MC, Martins ML, Silva N, Gomes A. Soft tissue pharmacokinetics after oral administration of amoxicillin/clavulanic acid. Laryngoscope. 2000;110(6):1050–1055. doi:
    1. Passàli D, Mazzei T, Novelli A, Fallani S, Dentico P, Mezzedimi C, et al. Amoxicillin/clavulanate in chronic rhinosinusitis: tissue and serum distribution. Acta Otorhinolaryngol Belg. 2001;55(3):259–264.
    1. Jehl F, Klossek JM, Peynegre R, Serrano E, Castillo L, Bobin S, et al. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily]. Presse Med. 2002;31(34):1596–1603.
    1. Williamson IG, Rumsby K, Benge S, Moore M, Smith PW, Cross M, et al. Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis: a randomized controlled trial. JAMA. 2007;298(21):2487–2496. doi:
    1. Garbutt JM, Banister C, Spitznagel E., Piccirillo JF. Amoxicillin for acute rhinosinusitis: a randomized controlled trial. JAMA.2012;307(7):685–692. doi:
    1. Wald ER, Chiponis D, Ledesma-Medina J. Comparative effectiveness of amoxicillin and amoxicillin-clavulanate potassium in acute paranasal sinus infections in children: a double-blind placebo-controlled trial. Pediatrics. 1986;77(6):795–780.
    1. Bucher HC, Tschudi P, Young J, Périat P, Welge-Lüssen A, Züst H, et al., BASINUS (Basel Sinusitis Study). Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice. Arch Intern Med. 2003;163(15):1793–1798. doi:
    1. Wald ER, Nash D, Eickhoff J. Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial sinusitis in children. Pediatrics. 2009;124(1):9–15. doi:
    1. Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E, 556 Clinical Study Group. The efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate 2000/125 mg, twice daily, versus oral amoxicillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia. Int J Antimicrob Agents. 2002;20(2):119–129.
    1. Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother. 2005;49(1):153–160. doi:
    1. Garau J, Twynholm M, Garcia-Mendez E, Siquier B, Rivero A, 557 Clinical Study Group. Oral pharmacologically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother. 2003;52(5):826–836. doi:
    1. Merenstein D, Whittaker C, Chadwell T, Wegner B, D’Amico F. Are antibiotics beneficial for patients with sinusitis complaints? A randomized double-blind clinical trial. J Fam Pract. 2005;54(2):144–151.
    1. Fisher D, Stewart AL, Bloch DA, Lorig K, Laurent D, Holman H. Capturing the patient’s view of change as a clinical outcome measure. JAMA. 1999;282(12):1157–1162.
    1. Falagas MF, Giannopoulou K, Vardakas KZ, Dimopoulos G, Karageorgopoulos DE. Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8(9):543–552. doi:
    1. Krober MS, Bass JW, MIchels GN. Streptococcal pharyngitis: placebo-controlled double-blind evaluation of clinical response to penicillin therapy. JAMA. 1985;253(9):1271–1274.
    1. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385:1729–1737. doi:
    1. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–463. doi:
    1. Mayo Clinic. Chronic sinusitis. Available at . Accessed on May 25, 2014.
    1. Garbutt J, Spitznagel E, Piccirillo J. Use of the modified SNOT-16 in primary care patients with clinically diagnosed acute rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2011:137(8):792–797. doi:
    1. Quadri N, Lloyd A, Keating KN, Nafees B, Piccirillo J, Wild D. Psychometric evaluation of the Sinonasal Outcome Test-16 and activity impairment assessment in acute bacterial sinusitis. Otolaryngol Head Neck Surg. 2013;149(1):161–167. doi:
    1. Sealed envelope. Power (sample size) calculators. Available at . Accessed last on May 27, 2017.
    1. Kaye CM, Allen A, Perry S, McDonagh M, Davy M, Storm K, et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther. 2001;23(4):578–584.
    1. Vree TB, Dammers E, Exler PS. Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects. J Antimicrob Chemother. 2003;51(2):373–378.
    1. Hoffman A, Danenberg HD, Katzhendler I, Shuval R, Gilhar D, Friedman M. Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form. J Control Release. 1998;54(1):29–37.
    1. Revicki DA, Kaplan RM. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Qual Life Res. 1993;2(6):477–487.
    1. Guyatt GH, Norman GR, Juniper EF, Griffith LE. A critical look at transition ratings. J Clin Epidemiol. 2002;55(9):900–908.
    1. Metz SM, Wyrwich KW, Babu AN, Kroenke K, Tierney WM, Wolinsky FD. Validity of patient-reported health-related quality of life global ratings of change using structural equation modeling. Qual Life Res. 2007;16(7):1193–1202. doi:
    1. Stiel S, Kues K, Krumm N, Radbruch L, Elsner F. Assessment of quality of life in patients receiving palliative care: comparison of measurement tools and single item on subjective well-being. J Palliat Med. 2011;14(5):599–606. doi:
    1. Godil SS, Parker SL, Zuckerman SL, Mendenhall SK, Devin CJ, Asher AL, et al. Determining the quality and effectiveness of surgical spine care: patient satisfaction is not a valid proxy. Spine J. 2013;13(9):1006–1012. doi:
    1. Conrad R, Mücke M, Marinova M, Burghardt A, Stieber C, Cuhis H, et al. Measurement of quality of life in palliative care: evidence for criterion-oriented validity of a single-item approach. J Palliat Med. 2017. January 5 doi: [Epub ahead of print].
    1. Kronzer VL, Jerry MR, Abdallah B, Wildes TS, McKinnon SL, Sharma A, et al. Changes in quality of life after elective surgery: an observational study comparing two measures. Qual Life Res. 2017. March 29 doi: [Epub ahead of print]
    1. Rothman KJ. No adjustments are needed for multiple comparisons. Epidem. 1990;1(1):43–46.
    1. Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis (Review). Cochrane Database Syst Rev. 2013. December 2;(12):CD005149 doi:
    1. King D, Mitchell B, Willams CP, Spurling GKP. Nasal saline irrigation for acute upper airway infection symptoms. Cochrane Database Syst Rev. 2015. April 20;(4): CD006821 doi:

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться